je.st
news
Tag: findings
Item 660 Ex A Further Findings
2016-06-04 01:12:34| PortlandOnline
PDF Document, 1,549kbCategory: Current Agenda Items
Item 651 Design Commission findings
2016-06-03 21:07:40| PortlandOnline
PDF Document, 3,812kbCategory: Current Agenda Items
Tags: design
item
commission
findings
South Portland | 6-2-16 | 2750 SW Moody Ave | Adjustment Review w/ Design Modication - Final Findings | LU 15-279775 DZM AD GW
2016-06-03 00:55:21| PortlandOnline
PDF Document, 1,958kbCategory: Southwest Neighborhoods, Inc. Decisions
Tags: design
review
south
final
New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
2016-05-16 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 7, 2016. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Kim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sullivan Gulch | 5-13-16 | 1177 NE 21st Ave | Adjustment Review - Tentative Final Findings | LU 15-277355 AD
2016-05-13 18:07:40| PortlandOnline
PDF Document, 2,120kbCategory: Northeast Coalition of Neighbors
Sites : [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] next »